PREOS

AcronymDefinition
PREOSPrediction of Performance & Range for Electro-Optical Systems
PREOSPeng-Robinson Equation of State (chemical engineering)
References in periodicals archive ?
The new 2-year data show that women who followed Preos therapy with Fosamax continued gaining lumbar spine bone density, for an overall gain of 12%, compared with baseline (N.
We believe our promotion of Kineret will help to introduce NPS to the rheumatology community and enhance our ability to also market Preos once it is approved.
An expanded new drug application package for the company's proprietary formulation, Preos, was planned for February 2005, according to the NPS Web site.
Client Configuration Toolkit - Software tool that helps enable IT to configure BIOS without a desk side visit either one-to-one or one-to-many in a preOS or post-OS environment.
The UEFI Forum will participate in the following DMTF work groups: Desktop & Mobile, Server Management, CIM Core Schema and PreOS, as well as the SMBIOS Sub-team.
The complaint alleges that during the Class Period, defendants made false and misleading statements regarding the Company's business and prospects, including the potential for success of PREOS, its full-length human parathyroid hormone (PTH) drug candidate being developed for the treatment of osteoporosis.
Specifically, Defendants concealed: (1) results of the PaTH study evidenced that PEROS was not different from Fosamax in both bone density and fracture results; (2) there was a very small market for this type of drug; (3) a major study concluded that more studies would be needed to determine efficacy; and, (4) PREOS could not be prescribed for broader fracture uses.
Specifically, the Complaint alleges that during the Class Period, defendants made false and misleading statements regarding the Company's business and prospects, including the potential for success of PREOS, its full-length human parathyroid hormone (PTH) drug candidate being developed for the treatment of osteoporosis.
The upgrade came as a result of recent due diligence which Lehman believes suggests an improved risk/reward profile on the regulatory review and commercial potential of NPSP's osteoporosis drug Preos.
On October 20, 2004, NPS Pharmaceuticals' (NASDAQ:NPSP) shares fell after presenting additional Preos data at the American College of Rheumatology.